论文部分内容阅读
[目的]探讨拉米夫定(LAM)联合中药治疗慢性乙型肝炎(CHB)的临床疗效。[方法]将212例CHB患者随机分为治疗组(110例)与对照组(102例)。治疗组给予LAM联合中药治疗;对照组单用LAM治疗。LAM100 mg/d,疗程12个月;中医辨证治疗,根据不同证型,辨证施治,每日服中药1剂,疗程>8个月。随访1 a。[结果]治疗6、12个月及随访1 a时,治疗组的丙氨酸氨基转移酶(ALT)复常率、HBeAg转阴率、HBeAg血清转换率均明显高于对照组(P<0.01)。HBV-DNA转阴率2组在治疗3、6个月时段差异无统计学意义,而在12个月及随访1 a时段,差异有统计学意义(P<0.01)。[结论]LAM联合中药治疗,可提高CHB患者抗病毒治疗的持续应答率,减少停药后的病情复发,提高临床疗效。
[Objective] To investigate the clinical efficacy of lamivudine combined with traditional Chinese medicine in the treatment of chronic hepatitis B (CHB). [Methods] 212 CHB patients were randomly divided into treatment group (110 cases) and control group (102 cases). The treatment group was treated with LAM combined with traditional Chinese medicine; the control group with LAM alone. LAM100 mg / d, treatment for 12 months; TCM syndrome differentiation treatment, according to different syndromes, syndrome differentiation, daily serving a Chinese medicine, treatment> 8 months. Follow-up 1 a. [Results] The ALT normalization rate, HBeAg negative conversion rate and HBeAg seroconversion rate in the treatment group were significantly higher than those in the control group (P <0.01) ). There was no significant difference in HBV-DNA negative rate between the two groups at 3 and 6 months, but there was significant difference between the two groups (P <0.01) at 12 months and follow-up period of 1 year. [Conclusion] LAM combined with traditional Chinese medicine treatment can improve the sustained response rate of antiviral therapy in patients with CHB, reduce the recurrence of disease after stopping drug therapy and improve the clinical efficacy.